Skip to main content
icon for Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

icon for Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

Wen wird Trump als nächsten FDA-Kommissar bekannt geben?

Kyle Diamantas 13%

Brett Giroir 8.2%

Sara Brenner 7.2%

Stephen Hahn 6.2%

Polymarket

$18,953 Vol.

Kyle Diamantas 13%

Brett Giroir 8.2%

Sara Brenner 7.2%

Stephen Hahn 6.2%

Polymarket

$18,953 Vol.

Kyle Diamantas

$6,163 Vol.

27%

Stephen Hahn

$1,802 Vol.

6%

Brett Giroir

$3,007 Vol.

8%

Grace Graham

$4,151 Vol.

4%

Sara Brenner

$2,798 Vol.

7%

Keine Bekanntgabe bis zum 31. Dezember

$1,032 Vol.

32%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$18,953
Enddatum
31. Dez. 2026
Markt eröffnet
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$18,953
Enddatum
31. Dez. 2026
Markt eröffnet
May 12, 2026, 7:59 PM ET
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

Vorsicht bei externen Links.

Häufig gestellte Fragen

„Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ist ein Prognosemarkt auf Polymarket mit 6 möglichen Ergebnissen, bei dem Händler Anteile auf Basis ihrer Einschätzung kaufen und verkaufen. Das aktuell führende Ergebnis ist „Keine Bekanntgabe bis zum 31. Dezember" mit 32%, gefolgt von „Kyle Diamantas" mit 27%. Die Preise spiegeln Echtzeit-Wahrscheinlichkeiten der Community wider. Ein Anteilspreis von 32¢ bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 32% zuweist. Diese Quoten ändern sich laufend, wenn Händler auf neue Entwicklungen reagieren. Anteile am richtigen Ergebnis können bei Marktauflösung für jeweils $1 eingelöst werden.

Stand heute hat „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ein Gesamthandelsvolumen von $19K generiert, seit der Markt am May 12, 2026 gestartet wurde. Dieses Aktivitätsniveau spiegelt starkes Engagement der Polymarket-Community wider und stellt sicher, dass die aktuellen Quoten von einem breiten Pool an Marktteilnehmern geprägt werden. Sie können Live-Preisbewegungen verfolgen und direkt auf dieser Seite auf jedes Ergebnis handeln.

Um auf „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" zu handeln, durchsuchen Sie die 6 verfügbaren Ergebnisse auf dieser Seite. Jedes Ergebnis zeigt einen aktuellen Preis, der die implizierte Wahrscheinlichkeit des Marktes darstellt. Um eine Position einzunehmen, wählen Sie das Ergebnis, das Sie für am wahrscheinlichsten halten, wählen Sie „Ja" um dafür oder „Nein" um dagegen zu handeln, geben Sie Ihren Betrag ein und klicken Sie auf „Handeln". Liegt Ihr gewähltes Ergebnis bei Marktauflösung richtig, zahlen Ihre „Ja"-Anteile jeweils $1 aus. Liegt es falsch, zahlen sie $0. Sie können Ihre Anteile auch jederzeit vor der Auflösung verkaufen.

Der aktuelle Favorit für „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" ist „Keine Bekanntgabe bis zum 31. Dezember" mit 32%, was bedeutet, dass der Markt diesem Ergebnis eine Wahrscheinlichkeit von 32% zuweist. Das nächstliegende Ergebnis ist „Kyle Diamantas" mit 27%. Diese Quoten werden in Echtzeit aktualisiert, wenn Händler Anteile kaufen und verkaufen. Schauen Sie regelmäßig vorbei oder speichern Sie diese Seite als Lesezeichen.

Die Auflösungsregeln für „Wen wird Trump als nächsten FDA-Kommissar bekannt geben?" definieren genau, was passieren muss, damit jedes Ergebnis als Gewinner erklärt wird – einschließlich der offiziellen Datenquellen zur Bestimmung des Ergebnisses. Sie können die vollständigen Auflösungskriterien im Abschnitt „Regeln" auf dieser Seite über den Kommentaren einsehen. Wir empfehlen, die Regeln vor dem Handeln sorgfältig zu lesen, da sie die genauen Bedingungen, Sonderfälle und Quellen festlegen.